Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00062374
Other study ID # NCI-2012-01438
Secondary ID 03-032NCI-5917CD
Status Completed
Phase Phase 2
First received June 5, 2003
Last updated June 3, 2013
Start date June 2003

Study information

Verified date June 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surgery.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the correlation of FDG-PET/CT imaging early in the preoperative treatment program of locally advanced gastric cancer with histologic response assessment and patient outcome, defined as overall and progression-free survival.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy and safety of preoperative chemotherapy with irinotecan and cisplatin in the treatment of locally advanced gastric cancer.

II. To examine the biology of locally advanced gastric cancer and the response to chemotherapy by DNA microarray technology and by histopathology.

III. To obtain preliminary data on biodistribution, dosimetry and explore the potential clinical usefulness of FLT PET in patients with locally advanced gastric cancer undergoing a novel combination neoadjuvant chemotherapy.

OUTLINE: This is an open-label, nonrandomized, multicenter study.

Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection.

Patients undergo fluorodeoxyglucose FDG-PET/CT at baseline. Some patients undergo additional FDG-PET/CT scans in weeks 3 and 6. Approximately 5 patients undergo fluorothymidine FLT-PET/CT at baseline, during week 3, and/or before surgical resection.

Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal (GE) junction

- Tumors involving the GE junction must have the bulk of disease in the stomach

- Siewert's type II and III tumors involving the GE junction are eligible

- Tumors of the distal esophagus that extend less than 2 cm into the stomach are ineligible

- Locally advanced disease that is potentially curable by surgery

- Any T, N+, M0 or T3-T4, any N, M0 by staging CT scan and laparoscopy or endoscopic ultrasound

- No T1-T2, N0, M0 tumors

- No metastatic disease

- Any suspected sites of M1 disease must be proven to be M0

- Performance status - Karnofsky 60-100%

- Performance status - ECOG 0-2

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 mg/dL

- Creatinine no greater than 1.5 mg/dL

- No history of active angina

- No New York Heart Association class III or IV heart disease

- No myocardial infarction within the past 6 months

- No history of significant ventricular arrhythmia requiring antiarrhythmic medication

- No history of clinically significant conduction system abnormality

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No concurrent serious infection

- No other uncontrolled medical illness that would preclude study participation

- No psychiatric illness that would preclude study compliance

- No clinically significant auditory impairment

- No pre-existing peripheral neuropathy grade 2 or greater

- No other active malignancy within the past 5 years except nonmelanoma skin cancer, nonmetastatic prostate cancer, or carcinoma in situ of the cervix

- Able to tolerate the proposed study surgical procedure and chemotherapy regimen

- No prior biologic therapy for this disease

- No prior chemotherapy for this disease

- No other concurrent chemotherapy

- No prior radiotherapy for this disease

- See Disease Characteristics

- No concurrent vitamins, antioxidants, or herbal preparations or supplements

- A single daily multivitamin tablet is allowed

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
irinotecan hydrochloride
Given IV
cisplatin
Given IV
Procedure:
conventional surgery
Undergo radical subtotal or total gastrectomy with lymph node dissection
positron emission tomography/computed tomography
Undergo FDG-PET/CT
Radiation:
fludeoxyglucose F 18
Undergo FDG-PET/CT
Procedure:
positron emission tomography/computed tomography
Undergo FLT-PET/CT
Other:
fluorine F 18 fluorothymidine
Undergo FLT-PET/CT

Locations

Country Name City State
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Histological response determined by a significant drop in FDG uptake correlates Using a two sample t-test with 30 evaluable patients, we would be able to adequately test that the decrease in SUV early in the treatment plan is significantly different between responders and non responders. Day 15 No
See also
  Status Clinical Trial Phase
Recruiting NCT02291211 - S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis Phase 2
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Completed NCT01178944 - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Phase 2
Completed NCT00991952 - Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00006389 - Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer Phase 2
Terminated NCT01249443 - Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Phase 1
Completed NCT01612546 - Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT01939275 - 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer N/A
Active, not recruiting NCT01637805 - Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer Phase 1
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Withdrawn NCT02344810 - C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Phase 1/Phase 2
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT01839773 - A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy Phase 3
Completed NCT00084617 - Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Phase 2
Completed NCT00068380 - A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer Phase 2